Changes associated with percutaneous XXXX injection in the treatment of @entity9384 .

@entity1 @entity1378 @entity8681 @entity1068 @entity9384
Percutaneous @entity1068 injection ( @entity8681 ) is an alternative therapy for @entity9384 ( @entity9384 ). However, some concern is raised on its carcinogenic effects. To evaluate the cytological and clinical changes caused by @entity8681 in @entity1 with benign @entity9384 . Thirty-nine @entity1 with @entity9384 (23.1% hyperfunctioning) were submitted to a median of three @entity8681 sessions. After a median of 17 months, @entity1 were reassessed. A new ultrasound-guided fine needle biopsy (US-FNB) was performed, and the smears were analyzed after May-Gr  nwald-Giemsa staining. The diagnostic findings and the cellular characteristics were compared before and after treatment. There was an increase in the proportion of nondiagnostic/unsatisfactory results (from 2.5% to 18.9%). No malignant cases were observed. The proportion of moderate/intense macrophage infiltration decreased from 60% to 15%. Before treatment, 23.1% @entity1 had @entity1378 , which was completely or partially resolved in 66.7%. By ultrasound, the percentage of homogeneous nodules decreased from 64.0% to 38.4% (p=0.0235), and the mean nodule volume decreased from 13.4    12.2 to 5.3    5.1 cm(3). We demonstrate that @entity8681 increases the proportion of nondiagnostic/unsatisfactory results from US-FNB. Therefore, cytological findings after @entity8681 must be evaluated with caution. Our results also suggest that @entity8681 is an efficacious and safe therapeutic option, with no carcinogenic effects observed on cytological evaluations. Safety and efficacy must be evaluated in larger studies with longer follow-up periods.
